Canaccord analyst Mark Massaro said the decline in Quest Diagnostics shares following its Q2 miss and lowered top-line guidance was fair. Despite the miss, the analyst believes the story remains intact as he believes the company will take market share, is poised to win more business, and he expects the pace of M&A to increase. Massaro reiterated his Buy rating and lowered his price target to $118 from $122 on Quest Diagnostics shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.